UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/519,792	03/28/2005	Kenji Hashimoto	2004 2053A	3058
	7590 03/11/200 , LIND & PONACK, I	EXAMINER		
1030 15th Street, N.W., Suite 400 East Washington, DC 20005-1503			KINGAN, TIMOTHY G	
			ART UNIT	PAPER NUMBER
			1797	
			MAIL DATE	DELIVERY MODE
			03/11/2009	PAPER

## Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

## Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
10/519,792	HASHIMOTO ET AL.	
Examiner	Art Unit	

	HWOTH G. KINGAN	1797	
The MAILING DATE of this communication appe	ars on the cover sheet with the c	correspondence add	ress
THE REPLY FILED <u>02 March 2009</u> FAILS TO PLACE THIS AP	PLICATION IN CONDITION FOR A	ALLOWANCE.	
1.  The reply was filed after a final rejection, but prior to or on application, applicant must timely file one of the following application in condition for allowance; (2) a Notice of Appe for Continued Examination (RCE) in compliance with 37 C periods:	replies: (1) an amendment, affidaviral (with appeal fee) in compliance	t, or other evidence, w with 37 CFR 41.31; or	hich places the (3) a Request
a) The period for reply expiresmonths from the mailing	date of the final rejection.		
b) The period for reply expires on: (1) the mailing date of this Air no event, however, will the statutory period for reply expire la Examiner Note: If box 1 is checked, check either box (a) or (I MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f	ter than SIX MONTHS from the mailing b). ONLY CHECK BOX (b) WHEN THE ).	g date of the final rejection FIRST REPLY WAS FI	on. LED WITHIN TWO
Extensions of time may be obtained under 37 CFR 1.136(a). The date of have been filed is the date for purposes of determining the period of extunder 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL	ension and the corresponding amount of the hortened statutory period for reply origi	of the fee. The appropria nally set in the final Offic	ate extension fee e action; or (2) as
2. The Notice of Appeal was filed on A brief in comp	iance with 37 CFR 41.37 must be t	filed within two month	s of the date of
filing the Notice of Appeal (37 CFR 41.37(a)), or any exter Notice of Appeal has been filed, any reply must be filed wi AMENDMENTS	sion thereof (37 CFR 41.37(e)), to	avoid dismissal of the	
3. The proposed amendment(s) filed after a final rejection, b	out prior to the date of filing a brief,	will not be entered be	cause
(a) ☐ They raise new issues that would require further cor		ΓE below);	
(b) They raise the issue of new matter (see NOTE below	**		
(c) They are not deemed to place the application in bett	er form for appeal by materially red	ducing or simplifying t	ne issues for
appeal; and/or (d) ☐ They present additional claims without canceling a c	corresponding number of finally rois	otod claims	
NOTE: (See 37 CFR 1.116 and 41.33(a)).	orresponding number of finally reje	cted claims.	
4. The amendments are not in compliance with 37 CFR 1.12	21 Soo attached Notice of Non Co	mpliant Amondment (	DTOL 324)
<ul><li>5. Applicant's reply has overcome the following rejection(s):</li></ul>		mpilant Amendment (	F 10L-324).
<ul><li>6. Newly proposed or amended claim(s) would be all</li></ul>		imely filed amendmen	at canceling the
non-allowable claim(s).	owabie ii subiliitted iii a separate, t	inery nied amendmer	it cancelling the
7. For purposes of appeal, the proposed amendment(s): a) [ how the new or amended claims would be rejected is prov The status of the claim(s) is (or will be) as follows:		l be entered and an e	xplanation of
Claim(s) allowed:			
Claim(s) objected to:			
Claim(s) rejected: <u>1,8,9,11-13,16 and 18-22</u> .			
Claim(s) withdrawn from consideration:			
AFFIDAVIT OR OTHER EVIDENCE	before an an the date of filing a Nie		
<ol> <li>The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e).</li> </ol>			
9. The affidavit or other evidence filed after the date of filing a entered because the affidavit or other evidence failed to or showing a good and sufficient reasons why it is necessary	vercome <u>all</u> rejections under appea	ıl and/or appellant fail	s to provide a
10.   The affidavit or other evidence is entered. An explanation			
REQUEST FOR RECONSIDERATION/OTHER			
11. The request for reconsideration has been considered but See Continuation Sheet.		condition for allowan	ce because:
<ul><li>12. ☐ Note the attached Information <i>Disclosure Statement</i>(s). (</li><li>13. ☐ Other:</li></ul>	Р1 0/5в/08) Paper No(s)		
/Jill Warden/			
Supervisory Patent Examiner, Art Unit 1797			

Continuation of 11. does NOT place the application in condition for allowance because: In view of the amendments, rejections under 35 U.S.C. 112 are withdrawn. The cancelation of claim 7 is recognized. The declaration under 37 CFR 1.132 substantially restates arguments previously addressed in earlier office action. Specifically, measurements of D-ser in individuals with a diagnosis of schizophrenia would be recognized as meaningful, to one of ordinary skill in the art, not in isolation but only in the context of a comparison of such values to those from healthy individuals. Use, in data analysis, of statistical parameters such as standard deviations, as well as normalizations for decreasing the effect of variations in total serine between individuals, are within the technical reach of one of ordinary skill in the art. With regard to the racemase, one of ordinary skill would recognize the role of this enzyme in partially determining values of D-ser and its ratios to total serine would depend on factors such as its total expression as well as any alterations to its activity associated with genetic lesion or abnormal expression of regulatory proteins; further, the prior art suggests such considerations. The original rejections are maintained.